RenovoRx, Inc.
RNXT
$0.9403
$0.04695.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 114.21% | 358.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 114.21% | 358.14% | |||
| Cost of Revenue | 61.70% | -- | |||
| Gross Profit | 162.14% | 139.53% | |||
| SG&A Expenses | -3.12% | 42.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.26% | 23.63% | |||
| Operating Income | 13.89% | -18.16% | |||
| Income Before Tax | -19.63% | 15.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.63% | 15.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.63% | 15.91% | |||
| EBIT | 13.89% | -18.16% | |||
| EBITDA | 13.90% | -- | |||
| EPS Basic | -2.59% | 32.72% | |||
| Normalized Basic EPS | -2.70% | 32.68% | |||
| EPS Diluted | -2.59% | 32.72% | |||
| Normalized Diluted EPS | -2.70% | 32.68% | |||
| Average Basic Shares Outstanding | 16.50% | 25.05% | |||
| Average Diluted Shares Outstanding | 16.50% | 25.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||